Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment

Open access

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, and therapeutic options for advanced HCC are limited. Here, we observe that intestinal dysbiosis affects antitumor immune surveillance and drives liver disease progression towards cancer. Dysbiotic microbiota, as seen in Nlrp6 −/− mice, induces a Toll-like receptor 4 dependent expansion of hepatic monocytic myeloid-derived suppressor cells (mMDSC) and suppression of T-cell abundance. This phenotype is transmissible via fecal microbiota transfer and reversible upon antibiotic treatment, pointing to the high plasticity of the tumor microenvironment. While loss of Akkermansia muciniphila correlates with mMDSC abundance, its reintroduction restores intestinal barrier function and strongly reduces liver inflammation and fibrosis. Cirrhosis patients display increased bacterial abundance in hepatic tissue, which induces pronounced transcriptional changes, including activation of fibro-inflammatory pathways as well as circuits mediating cancer immunosuppression. This study demonstrates that gut microbiota closely shapes the hepatic inflammatory microenvironment opening approaches for cancer prevention and therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-31312-5

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Loss NLRP6 augments liver disease progression in NEMO∆hepa mice. a Macroscopic appearance of NEMO∆hepa and NEMO∆hepa/Nlrp6−/− livers at 52 weeks of age. b Quantification of liver tumors with a diameter larger than 1 cm in NEMO∆hepa (n = 13) and NEMO∆hepa/Nlrp6−/− (n = 8) livers; unpaired two-tailed Student’s t test, 95% CI −2.239 to −0.107, p = 0.0328. c Serum ALT and GLDH levels of 52-week-old NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 8)) and respective controls (WT (n = 6), Nlrp6−/− (n = 6)); one-way ANOVA with Tukey’s multiple comparisons test (ALT: WT vs. NEMO∆hepa, 95% CI −708.8 to −141.2, p = 0.0018; WT vs. NEMO∆hepa/Nlrp6−/−, 95% CI −1023 to −410.1, p = <0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −519.1 to −0.93, p = 0.0489, GLDH: WT vs. NEMO∆hepa, 95% CI −339.4 to −127.3, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−, 95% CI −494.2 to −265.1, p = <0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −243.1 to −49.49, p = 0.049). d Representative pictures of H&E-stained liver sections, immunohistochemical (IHC) staining of CD45 and Sirius red stained liver sections of 52-week-old WT, Nlrp6−/−, NEMO∆hepa, and NEMO∆hepa/Nlrp6−/− livers, representative of 2 independent experiments; Scale bar: 100 µm. e RT-qPCR analysis of pro-fibrotic mRNA expression (TGFβ, Col1a1) in whole liver of NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 11) and respective controls (WT (n = 6), Nlrp6−/− (n = 8)); one-way ANOVA with Sidak’s multiple comparisons test (TGFb: WT vs. NEMO∆hepa, 95% CI −0.661 to 0.8128, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−,95% CI –1.418 to −0.0483, p = 0.0328; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −1.252 to −0.0219, p = 0.0405; Col1a1: WT vs. NEMO∆hepa, 95% CI −13.08 to 10.38, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−,95% CI –26.78 to −3.865, p = 0.006; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −24.53 to −3.950, p = 0.004). f Representative pictures of immunofluorescence (IF) stainings of CD11b and CD8 of NEMO∆hepa, NEMO∆hepa/Nlrp6−/− and respective controls (WT, Nlrp6−/−). Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. g RT-qPCR analysis of inflammatory mRNA expression (TNFα, IL-1β,Tlr4) in whole liver of NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 11) and respective controls (WT (n = 4), Nlrp6−/− (n = 5)); one-way ANOVA with Sidak’s multiple comparisons test (Tnfa: WT vs. NEMO∆hepa, 95% CI −2.37 to 0.6196, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –4.04 to −0.806, p = 0.0015; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −2.505 to −0.006, p = 0.023; IL-1β: WT vs. NEMO∆hepa, 95% CI −1.45 to 1.72, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –2.90 to −0.1197, p = ns; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −2.601 to −0.1138, p = 0.047; Tlr4: WT vs. NEMO∆hepa, 95% CI −5.62 to 4.156, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –6.61 to −2.71, p = ns; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −8.989 to −1.323, p = 0.005). h Immunoblot analysis of liver protein extracts from 52-week-old mice of all indicated genotypes for JNK, p-JNK and GAPDH as loading control; representative of 2 experiment. i Histological quantification of Cleaved Caspase 3 positive cells per viewfield; NEMO∆hepa (n = 17) and NEMO∆hepa/Nlrp6−/− (n = 24) viewfields one-way ANOVA with Tukey’s multiple comparisons test (NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −8.141 to −3.410, p < 0.0001). j Representative pictures of IF staining of KI67. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. All Data are presented as the mean ± standard error of the mean (SEM). Experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
Fig. 1 Loss NLRP6 augments liver disease progression in NEMO∆hepa mice. a Macroscopic appearance of NEMO∆hepa and NEMO∆hepa/Nlrp6−/− livers at 52 weeks of age. b Quantification of liver tumors with a diameter larger than 1 cm in NEMO∆hepa (n = 13) and NEMO∆hepa/Nlrp6−/− (n = 8) livers; unpaired two-tailed Student’s t test, 95% CI −2.239 to −0.107, p = 0.0328. c Serum ALT and GLDH levels of 52-week-old NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 8)) and respective controls (WT (n = 6), Nlrp6−/− (n = 6)); one-way ANOVA with Tukey’s multiple comparisons test (ALT: WT vs. NEMO∆hepa, 95% CI −708.8 to −141.2, p = 0.0018; WT vs. NEMO∆hepa/Nlrp6−/−, 95% CI −1023 to −410.1, p = <0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −519.1 to −0.93, p = 0.0489, GLDH: WT vs. NEMO∆hepa, 95% CI −339.4 to −127.3, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−, 95% CI −494.2 to −265.1, p = <0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −243.1 to −49.49, p = 0.049). d Representative pictures of H&E-stained liver sections, immunohistochemical (IHC) staining of CD45 and Sirius red stained liver sections of 52-week-old WT, Nlrp6−/−, NEMO∆hepa, and NEMO∆hepa/Nlrp6−/− livers, representative of 2 independent experiments; Scale bar: 100 µm. e RT-qPCR analysis of pro-fibrotic mRNA expression (TGFβ, Col1a1) in whole liver of NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 11) and respective controls (WT (n = 6), Nlrp6−/− (n = 8)); one-way ANOVA with Sidak’s multiple comparisons test (TGFb: WT vs. NEMO∆hepa, 95% CI −0.661 to 0.8128, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−,95% CI –1.418 to −0.0483, p = 0.0328; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −1.252 to −0.0219, p = 0.0405; Col1a1: WT vs. NEMO∆hepa, 95% CI −13.08 to 10.38, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−,95% CI –26.78 to −3.865, p = 0.006; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −24.53 to −3.950, p = 0.004). f Representative pictures of immunofluorescence (IF) stainings of CD11b and CD8 of NEMO∆hepa, NEMO∆hepa/Nlrp6−/− and respective controls (WT, Nlrp6−/−). Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. g RT-qPCR analysis of inflammatory mRNA expression (TNFα, IL-1β,Tlr4) in whole liver of NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 11) and respective controls (WT (n = 4), Nlrp6−/− (n = 5)); one-way ANOVA with Sidak’s multiple comparisons test (Tnfa: WT vs. NEMO∆hepa, 95% CI −2.37 to 0.6196, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –4.04 to −0.806, p = 0.0015; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −2.505 to −0.006, p = 0.023; IL-1β: WT vs. NEMO∆hepa, 95% CI −1.45 to 1.72, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –2.90 to −0.1197, p = ns; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −2.601 to −0.1138, p = 0.047; Tlr4: WT vs. NEMO∆hepa, 95% CI −5.62 to 4.156, p = ns; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –6.61 to −2.71, p = ns; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −8.989 to −1.323, p = 0.005). h Immunoblot analysis of liver protein extracts from 52-week-old mice of all indicated genotypes for JNK, p-JNK and GAPDH as loading control; representative of 2 experiment. i Histological quantification of Cleaved Caspase 3 positive cells per viewfield; NEMO∆hepa (n = 17) and NEMO∆hepa/Nlrp6−/− (n = 24) viewfields one-way ANOVA with Tukey’s multiple comparisons test (NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −8.141 to −3.410, p < 0.0001). j Representative pictures of IF staining of KI67. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. All Data are presented as the mean ± standard error of the mean (SEM). Experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***) and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 2 Loss of NLRP6 results in intestinal dysbiosis and barrier impairment correlating with steatohepatitis activity and tumor burden. a Cecal microbiota composition of 13-week-old mice (WT (n = 8), Nlrp6−/− (n = 9), NEMO∆hepa (n = 13), NEMO∆hepa/Nlrp6−/− (n = 11)) was analyzed using 16S rRNA gene amplicon sequencing. Bar chart based on permutational multivariate analysis of variance (ADONIS) presenting the percentage of variance of the gut microbiota explained by the factors “Genotype” (R2 = 0.057, **p < 0.006), “Cage” (R2 = 0.073, **p < 0.004), “Nemo” (R2 = 0.079, **p < 0.002),” Line”. Genotype - all included genotypes; Cage – individual cages; Nemo – WT & Nlrp6−/− mice vs. NEMO∆hepa & NEMO∆hepa/Nlrp6−/−; Line – WT & NEMO∆hepa vs. Nlrp6−/− & NEMO∆hepa/Nlrp6−/− (R2 = 0.16, ***p < 0.001). b Analysis for differential abundance of microbiota via DESeq analysis of 13 weeks old NEMO∆hepa (n = 13) and NEMO∆hepa/Nlrp6−/− (n = 11) mice. c Linear discriminant analysis (LDA) of effect size (LEfSe) between NEMO∆hepa (n = 13) and NEMO∆hepa/Nlrp6−/− (n = 11). d Representative pictures of IF stainings of ZO-1 in ileum and colon of NEMO∆hepa, NEMO∆hepa/Nlrp6−/− and respective controls (WT, Nlrp6−/−). Nuclei were counterstained with DAPI, representative of 2 independent experiments; Scale bar: 100 µm. e, f Immunoblot analysis of ileum and colon protein extracts from 52-week-old mice for Occludin and β-actin as loading control of indicated genotypes, representative of 2 experiments. g RT-qPCR analysis of inflammatory mRNA expression (IL-1β, Il-18, TNFα, Mcp1, Ccl5) in the ileum of NEMO∆hepa (n = 12) and NEMO∆hepa/Nlrp6−/− (n = 12) mice, unpaired t-test (IL-1β: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.0235–2.421, p = 0.046; Il-18: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.0293–0.7369, p = 0.035; TNFα: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −0.210 to 0.595, p = n.s.; Mcp1: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.097–1.932, p = 0.032; Ccl5: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 1.023–4.706, p = 0.0038. h In vivo intestinal permeability assessed by oral gavage of FITC-dextran. Rel. induction of FITC-dextran permeability in NEMO∆hepa (n = 6) and NEMO∆hepa/Nlrp6−/− mice (n = 4), unpaired t-test: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.101–0.615, p = 0.012), pooled data from 2 independent experiments. i Strong correlation (Spearman) of intestinal barrier function evidenced by FITC-dextran permeability with tumor number in NEMO∆hepa (blue dots) and NEMO∆hepa/Nlrp6−/− (red dots) mice (8 pairs), p = 0.0012 (two-sided), r = 0.96. All Data are presented as the mean ± standard error of the mean (SEM; experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
Fig. 2 Loss of NLRP6 results in intestinal dysbiosis and barrier impairment correlating with steatohepatitis activity and tumor burden. a Cecal microbiota composition of 13-week-old mice (WT (n = 8), Nlrp6−/− (n = 9), NEMO∆hepa (n = 13), NEMO∆hepa/Nlrp6−/− (n = 11)) was analyzed using 16S rRNA gene amplicon sequencing. Bar chart based on permutational multivariate analysis of variance (ADONIS) presenting the percentage of variance of the gut microbiota explained by the factors “Genotype” (R2 = 0.057, **p < 0.006), “Cage” (R2 = 0.073, **p < 0.004), “Nemo” (R2 = 0.079, **p < 0.002),” Line”. Genotype - all included genotypes; Cage – individual cages; Nemo – WT & Nlrp6−/− mice vs. NEMO∆hepa & NEMO∆hepa/Nlrp6−/−; Line – WT & NEMO∆hepa vs. Nlrp6−/− & NEMO∆hepa/Nlrp6−/− (R2 = 0.16, ***p < 0.001). b Analysis for differential abundance of microbiota via DESeq analysis of 13 weeks old NEMO∆hepa (n = 13) and NEMO∆hepa/Nlrp6−/− (n = 11) mice. c Linear discriminant analysis (LDA) of effect size (LEfSe) between NEMO∆hepa (n = 13) and NEMO∆hepa/Nlrp6−/− (n = 11). d Representative pictures of IF stainings of ZO-1 in ileum and colon of NEMO∆hepa, NEMO∆hepa/Nlrp6−/− and respective controls (WT, Nlrp6−/−). Nuclei were counterstained with DAPI, representative of 2 independent experiments; Scale bar: 100 µm. e, f Immunoblot analysis of ileum and colon protein extracts from 52-week-old mice for Occludin and β-actin as loading control of indicated genotypes, representative of 2 experiments. g RT-qPCR analysis of inflammatory mRNA expression (IL-1β, Il-18, TNFα, Mcp1, Ccl5) in the ileum of NEMO∆hepa (n = 12) and NEMO∆hepa/Nlrp6−/− (n = 12) mice, unpaired t-test (IL-1β: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.0235–2.421, p = 0.046; Il-18: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.0293–0.7369, p = 0.035; TNFα: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −0.210 to 0.595, p = n.s.; Mcp1: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.097–1.932, p = 0.032; Ccl5: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 1.023–4.706, p = 0.0038. h In vivo intestinal permeability assessed by oral gavage of FITC-dextran. Rel. induction of FITC-dextran permeability in NEMO∆hepa (n = 6) and NEMO∆hepa/Nlrp6−/− mice (n = 4), unpaired t-test: NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 0.101–0.615, p = 0.012), pooled data from 2 independent experiments. i Strong correlation (Spearman) of intestinal barrier function evidenced by FITC-dextran permeability with tumor number in NEMO∆hepa (blue dots) and NEMO∆hepa/Nlrp6−/− (red dots) mice (8 pairs), p = 0.0012 (two-sided), r = 0.96. All Data are presented as the mean ± standard error of the mean (SEM; experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 3 mMDSC drive steatohepatitis activity in NEMO∆hepa/Nlrp6−/− mice. a Representative pictures of H&E-stained liver sections and immunohistochemical staining of KI67 stained liver sections of 13-week-old WT, Nlrp6−/−, NEMO∆hepa, and NEMO∆hepa/Nlrp6−/− livers; Scale bar: 100 µm. b Histological quantification of Ki67+ cells per viewfield (WT n = 18, Nlrp6−/− n = 12, NEMO∆hepa n = 36, NEMO∆hepa/Nlrp6−/− n = 35, one way ANOVA, Tukeys’s multiple comparison test:Ki67: WT vs. NEMO∆hepa, 95% CI −34 to −22, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−,95% CI –40 to −28, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −11.54 to −1.67, p = 0.0039). c Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of 13-week-old NEMO∆hepa (n = 13), NEMO∆hepa/Nlrp6−/− (n = 10) and respective controls (WT (n = 9), Nlrp6−/− (n = 8), one-way ANOVA, bonferroni’s multiple comparison test: ALT: WT vs. NEMO∆hepa, 95% CI −1.123 to −344.4, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−,95% CI –1700 to −875.6, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −931.8 to −177.0, p = 0.002; AST: WT vs. NEMO∆hepa, 95% CI −764 to −210, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−, 95% CI –1147 to −588, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −1.735 to −0.2338, p < 0.001). d Representative pictures and e quantification of immunohistochemical (IHC) staining of CD45 stained liver sections of 13-week-old mice (WT(n = 4), Nlrp6−/− (n = 3), NEMO∆hepa (n = 13), and NEMO∆hepa/Nlrp6−/− (n = 8), one way ANOVA, Tukey’s multiple comparisons test, WT vs. NEMO∆hepa/Nlrp6−/−,95% CI −2855 to −0.8097, p < 0.001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/− 95% CI −7.5 to −0.8, p = 0.007); Scale bar: 200 µm. f Flow cytometry analysis of monocytic myeloid-derived suppressor cells (mMDSC) isolated from whole liver of 13-week-old NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 11) and respective controls (WT (n = 7), Nlrp6−/− (n = 8) one-way ANOVA, Sidak’s multiple comparison test: WT vs. NEMO∆hepa, 95% CI −10.1 to −2.7, p = 0.0002; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –11.8 to −4.2, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −7.5 to −0.8, p = 0.009). g The percentage of mMDSCs of CD45+ living cells strongly correlates with ALT levels in NEMO∆hepa and NEMO∆hepa/Nlrp6-/- mice (Spearman, 23 pairs). h Flow cytometry analysis of CD3+CD8+ cytotoxic T cells isolated from whole liver of 13-week-old NEMO∆hepa (n = 14), NEMO∆hepa/Nlrp6−/− (n = 10) and respective controls (WT (n = 9), Nlrp6−/− (n = 9); one-way ANOVA: Sidak’s multiple comparison test: WT vs. NEMO∆hepa, 95% CI −12.4 to −8.0, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 5.3 to −9.5, p < 0.0001. i Percentage of mMDSCs of CD45+ living cells and CD8+ cytotoxic T-cells is inversely correlated (Spearman 18 pairs). j In vitro T-cell proliferation assay. T cells were co-cultured with granulocytic MDSCs or monocytic MDSCs, representative of 2 experiments. All Data are presented as the mean ± standard error of the mean (SEM) Experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
Fig. 3 mMDSC drive steatohepatitis activity in NEMO∆hepa/Nlrp6−/− mice. a Representative pictures of H&E-stained liver sections and immunohistochemical staining of KI67 stained liver sections of 13-week-old WT, Nlrp6−/−, NEMO∆hepa, and NEMO∆hepa/Nlrp6−/− livers; Scale bar: 100 µm. b Histological quantification of Ki67+ cells per viewfield (WT n = 18, Nlrp6−/− n = 12, NEMO∆hepa n = 36, NEMO∆hepa/Nlrp6−/− n = 35, one way ANOVA, Tukeys’s multiple comparison test:Ki67: WT vs. NEMO∆hepa, 95% CI −34 to −22, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−,95% CI –40 to −28, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −11.54 to −1.67, p = 0.0039). c Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of 13-week-old NEMO∆hepa (n = 13), NEMO∆hepa/Nlrp6−/− (n = 10) and respective controls (WT (n = 9), Nlrp6−/− (n = 8), one-way ANOVA, bonferroni’s multiple comparison test: ALT: WT vs. NEMO∆hepa, 95% CI −1.123 to −344.4, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−,95% CI –1700 to −875.6, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −931.8 to −177.0, p = 0.002; AST: WT vs. NEMO∆hepa, 95% CI −764 to −210, p < 0.0001; WT vs. NEMO∆hepa/Nlrp6−/−, 95% CI –1147 to −588, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −1.735 to −0.2338, p < 0.001). d Representative pictures and e quantification of immunohistochemical (IHC) staining of CD45 stained liver sections of 13-week-old mice (WT(n = 4), Nlrp6−/− (n = 3), NEMO∆hepa (n = 13), and NEMO∆hepa/Nlrp6−/− (n = 8), one way ANOVA, Tukey’s multiple comparisons test, WT vs. NEMO∆hepa/Nlrp6−/−,95% CI −2855 to −0.8097, p < 0.001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/− 95% CI −7.5 to −0.8, p = 0.007); Scale bar: 200 µm. f Flow cytometry analysis of monocytic myeloid-derived suppressor cells (mMDSC) isolated from whole liver of 13-week-old NEMO∆hepa (n = 12), NEMO∆hepa/Nlrp6−/− (n = 11) and respective controls (WT (n = 7), Nlrp6−/− (n = 8) one-way ANOVA, Sidak’s multiple comparison test: WT vs. NEMO∆hepa, 95% CI −10.1 to −2.7, p = 0.0002; Nlrp6−/− vs. NEMO∆hepa/Nlrp6−/−, 95% CI –11.8 to −4.2, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI −7.5 to −0.8, p = 0.009). g The percentage of mMDSCs of CD45+ living cells strongly correlates with ALT levels in NEMO∆hepa and NEMO∆hepa/Nlrp6-/- mice (Spearman, 23 pairs). h Flow cytometry analysis of CD3+CD8+ cytotoxic T cells isolated from whole liver of 13-week-old NEMO∆hepa (n = 14), NEMO∆hepa/Nlrp6−/− (n = 10) and respective controls (WT (n = 9), Nlrp6−/− (n = 9); one-way ANOVA: Sidak’s multiple comparison test: WT vs. NEMO∆hepa, 95% CI −12.4 to −8.0, p < 0.0001; NEMO∆hepa vs. NEMO∆hepa/Nlrp6−/−, 95% CI 5.3 to −9.5, p < 0.0001. i Percentage of mMDSCs of CD45+ living cells and CD8+ cytotoxic T-cells is inversely correlated (Spearman 18 pairs). j In vitro T-cell proliferation assay. T cells were co-cultured with granulocytic MDSCs or monocytic MDSCs, representative of 2 experiments. All Data are presented as the mean ± standard error of the mean (SEM) Experiments are considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), and p < 0.0001 (****). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 4 Microbiota modulation reshapes the hepatic inflammatory microenvironment in NEMO∆hepa livers. a NEMO∆hepa and NEMO∆hepa/Nlrp6−/− mice were treated with broad-spectrum antibiotics (ABx) from week 8 till week 13. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of NEMO∆hepa (n = 12) and NEMO∆hepa/Nlrp6−/− with (n = 11) or without (n = 10) 5 weeks ABx treatment, control groups (–Abx) shared with Fig.3c, Fig.4e; one way ANOVA, Sidak’s multiple comparison test: ALT: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI −980.6 to −240.7, p = 0.0007; NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −316.0 to 405.4, p = n.s.; NEMOΔhepa/Nlrp6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI 277.8 to 1033, p = 0.0004; AST: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI 8.094 to 552.3, p = 0.047; NEMOΔhepa/Nlrp6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −399.3 to 120.6, p = n.s. b Flow cytometry analysis of monocytic myeloid-derived suppressor cells (mMDSC) and CD3+CD8+ cytotoxic T-cell isolated from whole liver of 13-week-old NEMO∆hepa (n = 12–14) and NEMO∆hepa/Nlrp6−/− with (n = 11) or without (n = 10–11) 5 wks Abx treatment control groups (–Abx) shared with Fig. 3d, f, one way ANOVA, Sidak’s multiple comparison test: CD11b: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI −7.624 to −1.307, p = 0.0036; NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −0.9433 to 5.374, p = n.s. NEMOΔhepa/Nlrp6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI 3454 to 9908, p < 0.0001; CD3+ CD8+: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI − 3.946 to 10.84, p < 0.0001; NEMOΔhepa vs. NEMOΔhepa/NLRP6−/−+ ABx, 95% CI −1.245 to 5.460, p = n.s.; NEMOΔhepa/NLRP6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −8.919 to −1.648, p = 0.003; control groups (–Abx) shared with Fig. 3f, h and (g), (h). c Representative pictures of immunofluorescence staining of CD11b of NEMO∆hepa and NEMO∆hepa/Nlrp6−/− with and without Abx treatment. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. d Analysis for differential abundance of microbiota via DESeq analysis of 13 weeks old NEMO∆hepa (n = 13) and NEMO∆hepa-FMT (n = 6) mice. NEMO∆hepa group shared with Fig. 2. e Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of NEMO∆hepa mice treated with NEMO∆hepa/Nlrp6−/− (+FMT, n = 5) microbiota or without treatment (−FMT, n = 12), control group (–FMT) shared with Fig.3c, (a). f Representative pictures of immunofluorescence staining of CD11b of NEMO∆hepa mice treated with +FMT or −FMT. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. g Flow cytometry analysis of monocytic myeloid derived suppressor cells (mMDSC) isolated from whole liver of NEMO∆hepa mice treated with +FMT (n = 5) or –FMT (n = 12) and NEMO∆hepa/Nlrp6−/− treated with +FMT (n = 4) or –FMT (n = 11), one way ANOVA, Holm–Sidak’s multiple comparison test: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, p = 0.005; NemoΔhepa vs. NemoΔhepa +FMT, p = 0.040.; control group (–FMT) shared with Fig.4b, Fig. 3f. h Flow cytometry analysis of CD3+CD8+ cytotoxic T-cell isolated from whole liver of NEMO∆hepa mice treated with +FMT (n = 5) or –FMT (n = 14) and NEMO∆hepa/Nlrp6−/− treated with +FMT (n = 4) or –FMT (n = 10), one-way ANOVA, Sidak’s multiple comparison test: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI 4.296 to 10.49, p < 0.0001; NemoΔhepa vs. NemoΔhepa + FMT, 95% CI 4.226 to 11.68, p < 0.0001; control group (–FMT) shared with (b), Fig. 3h. i Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of NEMO∆hepa/Tlr4−/− mice treated with NEMO∆hepa (n = 4) or NEMO∆hepa/Nlrp6−/− (n = 6) microbiota, unpaired t-test: AST: 95% CI −159.6 to 313.8, p = n.s., ALT: −711.9 to 713.5, p = n.s. j Flow cytometry analysis of mMDSC isolated from whole liver of NEMO∆hepa/Tlr4−/− mice treated with NEMO∆hepa (n = 4) or NEMO∆hepa/Nlrp6−/− (n = 6) microbiota and respective controls (NEMO∆hepa (n = 6) and NEMO∆hepa/Tlr4−/− mice (n = 8) without treatment), unpaired t-test: NEMOΔhepa/Tlr4−/− vs. NEMOΔhepa 95% CI −7.038 to −0.09878, p = 0.045. All Data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
Fig. 4 Microbiota modulation reshapes the hepatic inflammatory microenvironment in NEMO∆hepa livers. a NEMO∆hepa and NEMO∆hepa/Nlrp6−/− mice were treated with broad-spectrum antibiotics (ABx) from week 8 till week 13. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of NEMO∆hepa (n = 12) and NEMO∆hepa/Nlrp6−/− with (n = 11) or without (n = 10) 5 weeks ABx treatment, control groups (–Abx) shared with Fig.3c, Fig.4e; one way ANOVA, Sidak’s multiple comparison test: ALT: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI −980.6 to −240.7, p = 0.0007; NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −316.0 to 405.4, p = n.s.; NEMOΔhepa/Nlrp6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI 277.8 to 1033, p = 0.0004; AST: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI 8.094 to 552.3, p = 0.047; NEMOΔhepa/Nlrp6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −399.3 to 120.6, p = n.s. b Flow cytometry analysis of monocytic myeloid-derived suppressor cells (mMDSC) and CD3+CD8+ cytotoxic T-cell isolated from whole liver of 13-week-old NEMO∆hepa (n = 12–14) and NEMO∆hepa/Nlrp6−/− with (n = 11) or without (n = 10–11) 5 wks Abx treatment control groups (–Abx) shared with Fig. 3d, f, one way ANOVA, Sidak’s multiple comparison test: CD11b: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI −7.624 to −1.307, p = 0.0036; NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −0.9433 to 5.374, p = n.s. NEMOΔhepa/Nlrp6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI 3454 to 9908, p < 0.0001; CD3+ CD8+: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI − 3.946 to 10.84, p < 0.0001; NEMOΔhepa vs. NEMOΔhepa/NLRP6−/−+ ABx, 95% CI −1.245 to 5.460, p = n.s.; NEMOΔhepa/NLRP6−/− vs. NEMOΔhepa/Nlrp6−/− + ABx, 95% CI −8.919 to −1.648, p = 0.003; control groups (–Abx) shared with Fig. 3f, h and (g), (h). c Representative pictures of immunofluorescence staining of CD11b of NEMO∆hepa and NEMO∆hepa/Nlrp6−/− with and without Abx treatment. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. d Analysis for differential abundance of microbiota via DESeq analysis of 13 weeks old NEMO∆hepa (n = 13) and NEMO∆hepa-FMT (n = 6) mice. NEMO∆hepa group shared with Fig. 2. e Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels of NEMO∆hepa mice treated with NEMO∆hepa/Nlrp6−/− (+FMT, n = 5) microbiota or without treatment (−FMT, n = 12), control group (–FMT) shared with Fig.3c, (a). f Representative pictures of immunofluorescence staining of CD11b of NEMO∆hepa mice treated with +FMT or −FMT. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. g Flow cytometry analysis of monocytic myeloid derived suppressor cells (mMDSC) isolated from whole liver of NEMO∆hepa mice treated with +FMT (n = 5) or –FMT (n = 12) and NEMO∆hepa/Nlrp6−/− treated with +FMT (n = 4) or –FMT (n = 11), one way ANOVA, Holm–Sidak’s multiple comparison test: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, p = 0.005; NemoΔhepa vs. NemoΔhepa +FMT, p = 0.040.; control group (–FMT) shared with Fig.4b, Fig. 3f. h Flow cytometry analysis of CD3+CD8+ cytotoxic T-cell isolated from whole liver of NEMO∆hepa mice treated with +FMT (n = 5) or –FMT (n = 14) and NEMO∆hepa/Nlrp6−/− treated with +FMT (n = 4) or –FMT (n = 10), one-way ANOVA, Sidak’s multiple comparison test: NEMOΔhepa vs. NEMOΔhepa/Nlrp6−/−, 95% CI 4.296 to 10.49, p < 0.0001; NemoΔhepa vs. NemoΔhepa + FMT, 95% CI 4.226 to 11.68, p < 0.0001; control group (–FMT) shared with (b), Fig. 3h. i Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of NEMO∆hepa/Tlr4−/− mice treated with NEMO∆hepa (n = 4) or NEMO∆hepa/Nlrp6−/− (n = 6) microbiota, unpaired t-test: AST: 95% CI −159.6 to 313.8, p = n.s., ALT: −711.9 to 713.5, p = n.s. j Flow cytometry analysis of mMDSC isolated from whole liver of NEMO∆hepa/Tlr4−/− mice treated with NEMO∆hepa (n = 4) or NEMO∆hepa/Nlrp6−/− (n = 6) microbiota and respective controls (NEMO∆hepa (n = 6) and NEMO∆hepa/Tlr4−/− mice (n = 8) without treatment), unpaired t-test: NEMOΔhepa/Tlr4−/− vs. NEMOΔhepa 95% CI −7.038 to −0.09878, p = 0.045. All Data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 5 Akkermansia muciniphila supplementation ameliorates liver disease in NEMO∆hepa mice. a Inverse correlation (Spearman, 13 pairs) between mMDSC and abundance of A. muciniphila (AKK) in caeca of NEMO∆hepa mice. b Experimental setup: 8-week-old NEMO∆hepa mice were gavaged either with 2.1 × 108 CFU AKK or sterile anaerobic PBS for 5 weeks. c Principle Coordinates Analysis (PCoA) plot of microbiota (cecal content, stool) of NEMO∆hepa mice (n = 4) before and after AKK treatment. d Results of LDA effect size (LEfSe) of cecal microbiota of NEMO∆hepa mice (n = 4) before and after AKK treatment at bacterial taxa level. e Representative pictures of immunofluorescence staining of MUC2 in colon of NEMO∆hepa mice treated with PBS or AKK. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. f Representative pictures of immunofluorescence staining of ZO-1 in ileum and colon of NEMO∆hepa mice treated with PBS or AKK. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. g Immunoblot analysis of colon protein extracts from NEMO∆hepa mice either treated with PBS or AKK for 5 weeks for occludin and β-actin as loading control, representative of 2 experiments. h Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of NEMO∆hepa mice either treated with PBS (n = 6) or AKK (n = 8) for 5 weeks, unpaired t-test: ALT: NEMOΔhepa AKK vs. NEMOΔhepa PBS, 95% CI −835.1 to −312.4, p < 0.0001; AST: NEMOΔhepa AKK vs. NEMOΔhepa PBS, 95% CI −935.6 to −431.0, p < 0.0001. i Representative pictures of H&E-stained liver sections and immunofluorescence staining for CD11b in either PBS (n = 6) or AKK (n = 8) treated NEMO∆hepa mice. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. j RT-qPCR analysis of inflammatory and fibrotic mRNA expression (TGFβ, Col1a1, Mcp-1, Tlr4) in whole liver of NEMO∆hepa mice treated with PBS (n = 6) or AKK (n = 8) for 5 weeks, unpaired t-test, TGFβ: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.4772 to −0.03676, p = 0.026; Col1a1: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −1.023 to −0.1061, p = 0.019 Mcp-1: NEMOΔhepa AKK (n = 7) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.5069 to −0.1172, p = 0.0048; Tlr4: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.4238 to −0.07837, p = 0.008. All data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.001 (****), respectively. Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.
Fig. 5 Akkermansia muciniphila supplementation ameliorates liver disease in NEMO∆hepa mice. a Inverse correlation (Spearman, 13 pairs) between mMDSC and abundance of A. muciniphila (AKK) in caeca of NEMO∆hepa mice. b Experimental setup: 8-week-old NEMO∆hepa mice were gavaged either with 2.1 × 108 CFU AKK or sterile anaerobic PBS for 5 weeks. c Principle Coordinates Analysis (PCoA) plot of microbiota (cecal content, stool) of NEMO∆hepa mice (n = 4) before and after AKK treatment. d Results of LDA effect size (LEfSe) of cecal microbiota of NEMO∆hepa mice (n = 4) before and after AKK treatment at bacterial taxa level. e Representative pictures of immunofluorescence staining of MUC2 in colon of NEMO∆hepa mice treated with PBS or AKK. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. f Representative pictures of immunofluorescence staining of ZO-1 in ileum and colon of NEMO∆hepa mice treated with PBS or AKK. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. g Immunoblot analysis of colon protein extracts from NEMO∆hepa mice either treated with PBS or AKK for 5 weeks for occludin and β-actin as loading control, representative of 2 experiments. h Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels of NEMO∆hepa mice either treated with PBS (n = 6) or AKK (n = 8) for 5 weeks, unpaired t-test: ALT: NEMOΔhepa AKK vs. NEMOΔhepa PBS, 95% CI −835.1 to −312.4, p < 0.0001; AST: NEMOΔhepa AKK vs. NEMOΔhepa PBS, 95% CI −935.6 to −431.0, p < 0.0001. i Representative pictures of H&E-stained liver sections and immunofluorescence staining for CD11b in either PBS (n = 6) or AKK (n = 8) treated NEMO∆hepa mice. Nuclei were counterstained with DAPI, representative of 2 experiments; Scale bar: 100 µm. j RT-qPCR analysis of inflammatory and fibrotic mRNA expression (TGFβ, Col1a1, Mcp-1, Tlr4) in whole liver of NEMO∆hepa mice treated with PBS (n = 6) or AKK (n = 8) for 5 weeks, unpaired t-test, TGFβ: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.4772 to −0.03676, p = 0.026; Col1a1: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −1.023 to −0.1061, p = 0.019 Mcp-1: NEMOΔhepa AKK (n = 7) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.5069 to −0.1172, p = 0.0048; Tlr4: NEMOΔhepa AKK (n = 8) vs. NEMOΔhepa PBS (n = 6), 95% CI −0.4238 to −0.07837, p = 0.008. All data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.001 (****), respectively. Individual data points represent biological replicates unless otherwise stated. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 6 Hepatic bacterial 16s rDNA is increased in cirrhosis patients and shapes the hepatic transcriptomic landscape. a Study outline: Snap frozen surgical liver tissue specimen were taken from 44 cirrhosis patients that underwent liver transplantation or 11 healthy controls. DNA and mRNA were isolated from the same tissue specimen and tissue region and subjected to 16 s rRNA gene amplicon sequencing or mRNA sequencing. b 16s rRNA gene copies/ng DNA determined by real time quantitative PCR in control (n = 12) and cirrhotic (n = 43) liver (Mann–Whitney-U-Test, p = 0.014). c Pathway activity based on mRNA-sequencing data and inferred by PROGENy computational pathway analysis in cirrhosis patients (n = 22) vs. healthy controls (n = 8). Correlation of 16S rRNA gene abundance with pathway activation (Spearman correlation, n = 30 pairs). d Computational Cell type enrichment analysis and correlation of calculated cell types with 16S rRNA gene abundance of cirrhotic patients (n = 22) and healthy controls (n = 8). e 16S rRNA gene abundance strongly correlates with the expression of immune checkpoint genes (Spearman correlation, n = 30 pairs, two-tailed). f Correlation of CTLA4 and g transcription factors involved in T-cell exhaustion (TOX, IRF4) with rRNA gene copies/ng genomic DNA (Spearman, n = 30 pairs, all 2-tailed, p < 0.0001). All Data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). Source data are provided as a Source data file.
Fig. 6 Hepatic bacterial 16s rDNA is increased in cirrhosis patients and shapes the hepatic transcriptomic landscape. a Study outline: Snap frozen surgical liver tissue specimen were taken from 44 cirrhosis patients that underwent liver transplantation or 11 healthy controls. DNA and mRNA were isolated from the same tissue specimen and tissue region and subjected to 16 s rRNA gene amplicon sequencing or mRNA sequencing. b 16s rRNA gene copies/ng DNA determined by real time quantitative PCR in control (n = 12) and cirrhotic (n = 43) liver (Mann–Whitney-U-Test, p = 0.014). c Pathway activity based on mRNA-sequencing data and inferred by PROGENy computational pathway analysis in cirrhosis patients (n = 22) vs. healthy controls (n = 8). Correlation of 16S rRNA gene abundance with pathway activation (Spearman correlation, n = 30 pairs). d Computational Cell type enrichment analysis and correlation of calculated cell types with 16S rRNA gene abundance of cirrhotic patients (n = 22) and healthy controls (n = 8). e 16S rRNA gene abundance strongly correlates with the expression of immune checkpoint genes (Spearman correlation, n = 30 pairs, two-tailed). f Correlation of CTLA4 and g transcription factors involved in T-cell exhaustion (TOX, IRF4) with rRNA gene copies/ng genomic DNA (Spearman, n = 30 pairs, all 2-tailed, p < 0.0001). All Data are presented as the mean ± standard error of the mean (SEM) and considered significant at p < 0.05 (*), p < 0.01 (**), p < 0.001 (***). Source data are provided as a Source data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 91 references

Cited by

See all 241

Metadata

Authors
Schneider, K. M., Mohs, A., Gui, W., Galvez, E. J. C., Candels, L. S., Hoenicke, L., Muthukumarasamy, U., Holland, C. H., Elfers, C., Kilic, K., Schneider, C. V., Schierwagen, R., Strnad, P., Wirtz, T. H., Marschall, H.-U., Latz, E., Lelouvier, B., Saez-Rodriguez, J., de Vos, W., Strowig, T., Trebicka, J., & Trautwein, C.
Affiliations
  • Universitätsklinikum Aachen (DE)
  • Medizinische Hochschule Hannover (DE)
  • Heidelberg University (DE)
  • Goethe University Frankfurt (DE)
  • University of Gothenburg (SE)
  • University of Bonn (DE)
  • University of Helsinki (FI)
Corresponding author
Trautwein, Christian
Venue
Nature Communications
Published
2022-07-08
Volume
13
Issue
1
Pages
3964-3964
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4284975790
Cited by
225
References
91
Citations by year
2026: 44 · 2025: 65 · 2024: 58 · 2023: 51 · 2022: 7
FWCI
14.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Socio-Environmental Systems Modeling (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • DZNE Pub (submittedVersion, other-oa)
  • RWTH Publications (RWTH Aachen) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
  • RWTH Publications (RWTH Aachen)
Funders
Deutsche Forschungsgemeinschaft (Tr 285/10-2)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
hepatocellular carcinoma, gut microbiota, gut dysbiosis, myeloid-derived suppressor cells, TLR4, Akkermansia muciniphila, NLRP6, fecal microbiota transplantation, antibiotic therapy, T cell suppression, liver fibrosis, liver cirrhosis, intestinal barrier function, tumor immunosuppression, liver cancer prevention
MeSH terms
Gastrointestinal Microbiome, Animals, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Tumor Microenvironment, Microbiota, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. https://app.cochat.ai/papers/10.1038/s41467-022-31312-5
The paper
Schneider, K. M., Mohs, A., Gui, W., Galvez, E. J. C., Candels, L. S., Hoenicke, L., Muthukumarasamy, U., Holland, C. H., Elfers, C., Kilic, K., Schneider, C. V., Schierwagen, R., Strnad, P., Wirtz, T. H., Marschall, H.-U., Latz, E., Lelouvier, B., Saez-Rodriguez, J., de Vos, W., . . . Trautwein, C. (2022). Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nature Communications. https://doi.org/10.1038/s41467-022-31312-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.